Preliminary Characterization of a Leptin Receptor Knockout Rat Created by CRISPR/Cas9 System

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Bao, Dan ^a   Ma, Yuanwu ^a   Zhang, Xu ^a   Guan, Feifei ^a   Chen, Wei ^a   Gao, Kai ^a   Qin, Chuan ^b   Zhang, Lianfeng ^a  

^a BEIJING HOSPITAL   (China)

^b INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE BLOOD LEVEL; LEPTIN; LEPTIN RECEPTOR;

ANIMAL; ANIMAL MODEL; BONE DENSITY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DYSLIPIDEMIA; FEMUR; GENE INACTIVATION; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HOMEOSTASIS; HYPERGLYCEMIA; HYPERPHAGIA; METABOLISM; OBESITY; PROCEDURES; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; BONE DENSITY; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; DYSLIPIDEMIAS; FEMUR; GENE KNOCKOUT TECHNIQUES; GLUCOSE INTOLERANCE; HOMEOSTASIS; HYPERGLYCEMIA; HYPERPHAGIA; LEPTIN; MODELS, ANIMAL; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LEPTIN;

EID: 84946554605     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15942     Document Type: Article

References (38)

1. Hamrick, M. W. Leptin, bone mass, and the thrifty phenotype. J Bone Miner Res 19, 1607-1611, doi: 10.1359/JBMR.040712 (2004).
2. Chehab, F. F., Lim, M. E. & Lu, R. Correction of the sterility defect in homozygous obese female mice by treatment with the human recombinant leptin. Nat Genet 12, 318-320, doi: 10.1038/ng0396-318 (1996).
3. Ducy, P. et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100, 197-207 (2000).
4. Israel, D. & Chua, S., Jr. Leptin receptor modulation of adiposity and fertility. Trends Endocrinol Metab 21, 10-16, doi: 10.1016/j. tem.2009.07.004 (2010).
5. Chua, S. C., Jr. et al. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271, 994-996 (1996).
6. Coleman, D. L. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14, 141-148 (1978).
7. Halaas, J. L. et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269, 543-546 (1995).
8. Argiles, J. M. The obese Zucker rat: a choice for fat metabolism 1968-1988: twenty years of research on the insights of the Zucker mutation. Prog Lipid Res 28, 53-66 (1989).
9. Bray, G. A. & York, D. A. Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis. Physiol Rev 59, 719-809 (1979).
10. Bray, G. A. The Zucker-fatty rat: a review. Fed Proc 36, 148-153 (1977).
11. Wu-Peng, X. S. et al. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr): evidence for deficient plasma-to-CSF transport of leptin in both the Zucker and Koletsky obese rat. Diabetes 46, 513-518 (1997).
12. Crouse, J. A. et al. Altered cell surface expression and signaling of leptin receptors containing the fatty mutation. J Biol Chem 273, 18365-18373 (1998).
13. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821, doi: 10.1126/science.1225829 (2012).
14. Ma, Y., Zhang, L. & Huang, X. Genome modification by CRISPR/Cas9. FEBS J 281, 5186-5193, doi: 10.1111/febs.13110 (2014).
15. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823, doi: 10.1126/science.1231143 (2013).
16. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826, doi: 10.1126/science.1232033 (2013).
17. Cho, S. W., Kim, S., Kim, J. M. & Kim, J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31, 230-232, doi: 10.1038/nbt.2507 (2013).
18. Ma, Y. et al. Generation of eGFP and Cre knockin rats by CRISPR/Cas9. FEBS J 281, 3779-3790, doi: 10.1111/febs.12935 (2014).
19. Ma, Y. et al. Generating rats with conditional alleles using CRISPR/Cas9. Cell Res 24, 122-125, doi: 10.1038/cr.2013.157 (2014).
20. Popkin, B. M. Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases. Am J Clin Nutr 84, 289-298 (2006).
21. Tirabassi, R. S. et al. The BBZDR/Wor rat model for investigating the complications of type 2 diabetes mellitus. ILAR J 45, 292-302 (2004).
22. Calcutt, N. A., Cooper, M. E., Kern, T. S. & Schmidt, A. M. Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 8, 417-429, doi: 10.1038/nrd2476 (2009).
23. Katsuda, Y. et al. Diabetic complications in obese type 2 diabetic rat models. Exp Anim 63, 121-132 (2014).
24. Janghorbani, M., Van Dam, R. M., Willett, W. C. & Hu, F. B. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166, 495-505, doi: 10.1093/aje/kwm106 (2007).
25. Vestergaard, P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a metaanalysis. Osteoporos Int 18, 427-444, doi: 10.1007/s00198-006-0253-4 (2007).
26. Takaya, K. et al. Molecular cloning of rat leptin receptor isoform complementary DNAs-identification of a missense mutation in Zucker fatty (fa/fa) rats. Biochem Biophys Res Commun 225, 75-83, doi: 10.1006/bbrc.1996.1133 (1996).
27. Sreenan, S., Sturis, J., Pugh, W., Burant, C. F. & Polonsky, K. S. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 271, E742-747 (1996).
28. Reinwald, S., Peterson, R. G., Allen, M. R. & Burr, D. B. Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models. Am J Physiol Endocrinol Metab 296, E765-774, doi: 10.1152/ajpendo.90937.2008 (2009).
29. Tamasi, J. A., Arey, B. J., Bertolini, D. R. & Feyen, J. H. Characterization of bone structure in leptin receptor-deficient Zucker (fa/fa) rats. J Bone Miner Res 18, 1605-1611, doi: 10.1359/jbmr.2003.18.9.1605 (2003).
30. Glasow, A. et al. Expression of Ob receptor in normal human adrenals: differential regulation of adrenocortical and adrenomedullary function by leptin. J Clin Endocrinol Metab 83, 4459-4466, doi: 10.1210/jcem.83.12.5337 (1998).
31. Lutz, T. A. & Woods, S. C. Overview of animal models of obesity. Curr Protoc Pharmacol Chapter 5, Unit5 61, doi: 10.1002/0471141755.ph0561s58 (2012).
32. Coleman, D. L. & Hummel, K. P. The influence of genetic background on the expression of the obese (Ob) gene in the mouse. Diabetologia 9, 287-293 (1973).
33. Ma, Y. et al. Heritable multiplex genetic engineering in rats using CRISPR/Cas9. PLoS One 9, e89413, doi: 10.1371/journal. pone.0089413 (2014).
34. Lu, D. et al. Knockdown of cytochrome P450 2E1 inhibits oxidative stress and apoptosis in the cTnT(R141W) dilated cardiomyopathy transgenic mice. Hypertension 60, 81-89, doi: 10.1161/HYPERTENSIONAHA.112.191478 (2012).
35. Chen, H. et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84, 491-495 (1996).
36. Lee, G. H. et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 379, 632-635, doi: 10.1038/379632a0 (1996).
37. Chua, S. C., Jr. et al. Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes 45, 1141-1143 (1996).
38. Cohen, M. P. et al. Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists. A novel treatment strategy. J Clin Invest 95, 2338-2345, doi: 10.1172/JCI117926 (1995).